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ReseaRch on Methods – cost Methods
PRM8
disease BuRden of MultiPle MyeloMa in china
Liu Y.H.1, Liu G.2, Ren X.1, Zhang H.3, Huang Y.1
1Peking University, Beijing, China, 2Guanghua School of Management, Peking University, Beijing, 
China, 3Sun Yat-sen University, Guangzhou, China
Objectives: Multiple myeloma (MM) is known as an incurable cancer of plasma 
cells, which incurs significant burden on patients. There are estimated 27,000 MM 
patients in China in 2013, and the incidence is 1–4 per 100,000 people per year. 
However, the disease burden of MM in China has not been well studied. Using 
Guangzhou claim data, this article estimated the economic burden on patients with 
MM from a societal perspective. MethOds: 2009-2011 databases of Urban Employee 
Basic Medical Insurance and Urban Residents Basic Medical Insurance were used to 
estimate the direct medical cost of MM and the determinants of medical cost. The 
direct medical costs of bortezomib-based therapies and regular chemotherapies 
were compared. Disability Adjusted Life Year (DALY) was used to estimate the indi-
rect cost. Results: For a patients with MM conditions in Guangzhou, the direct cost 
was RMB 8.45 million in 2009, 8.52 million in 2010, and 13.90 million in 2011, while 
the indirect cost was RMB 12.18 million, 13.11 million, and 19.46 million, respectively. 
Moreover, the MM medical cost was higher with age, increasing reimbursement 
rate and length of stay. The average hospitalization expenditure for bortezomib-
based therapies and regular chemotherapies were RMB 60,945.84±38,335.12 and 
16,465.62±19,695.13 (P< 0.001). The out-of-pocket (OOP) cost for per treatment cycle 
were significantly higher for patients treated with bortezomib-based therapy (RMB 
43,773.57±12,415.07) than for those treated with regular chemotherapies (RMB 
3,720.74±4,060.65). cOnclusiOns: MM conditions have serious economic burdens, 
and was significantly increased overtime in China.MM patients would pay over 12 
times more OOP cost for the use of bortizomib-based therapy than for the use of 
commonly-used chemotherapies.
PRM9
health caRe use and oRal Medication PatteRns foR tyPe 2 diaBetes 
Patients in china: the Role of tRaditional chinese Medicines
Liu G.1, Xu F.2
1Guanghua School of Management, Peking University, Beijing, China, 2China Pharmaceutical 
University, Nanjing, China
Objectives: To investigate the health care utilization and cost, focusing on the use 
of oral anti-diabetic drugs (OADs) for type 2 diabetes patients in China. MethOds: 
A large scale, prospective, and observational study was conducted in 5 cities of 
China. Subjects on any OAD were enrolled. The data was collected from longitu-
dinal interviews and diary following-up with the enrolled patients. Primary data 
information included socio-demographic characteristics, health care and medica-
tion utilization and costs, laboratory assessments, and quality of life. The baseline 
interview and 4 times of following-up were conducted within 12 months. HbA1c, 
fasting blood-glucose and blood lipids were assessed. Multivariable regression and 
propensity score matching methods were used to control for confounding factors 
in the study. Results: 2886 patients enrolled at baseline, 2322 of them completed 
the full study. The average age of enrolled patients at baseline was 61.71(sd= 11.27) 
years. The number of OADs per patient was 1.66 (sd= 0.80) with a median of 2. The 
mostly used 4 OADs are: Metformin (44.01%), Acarbose (28.64%), XIaoke Pill (a tra-
ditional Chinese medicine, 20.54%) and Gliclazide (18.26%). On average, a patient 
spent CNY 8,867.56 (sd= 17,642.51) on health care annually, where OADs cost CNY 
2,645.82 (sd= 3,123.30). When controlling for other confounding variables via statisti-
cal models, further analysis finds that patients on XIaoke Pill as the major regimen 
ended up with a reduction in total health care cost by CNY 2,151 (p< 0.01), where 
OADs cost was reduced by about CNY 626 (p< 0.01). cOnclusiOns: Type 2 Diabetes 
patients in China bear a heavy economic burden. Among OADs, traditional Chinese 
medicine Xiaoke Pill appears to be a quite cost effective treatment regimen for 
diabetic patients in China. Future analysis is warranted to investigate mechanisms 
and conditions through which oral Chinese OADs may be cost effective for some 
diabetic patients in China.
PRM10
health econoMics Methodologies involving PaRkinson’s disease 
tReatMent in china
Low W.1, Azmi S.1, Yee S.L.1, Milea D.2
1Azmi Burhani Consulting, Petaling Jaya, Malaysia, 2Lundbeck Singapore Pte Ltd., Singapore
Objectives: To describe the methodologies used in health economics (HE) studies 
on Parkinson’s disease (PD) in China. MethOds: A structured literature review was 
conducted to describe the methodology used to generate HE evidence for PD treat-
ment in China. The review was conducted in both English and Mandarin languages 
using four databases: PubMed, Cochrane, WAN FANG and VIP, for articles published 
between 2000 and 2013. Study selection was limited to Chinese population based 
in China and those which reported cost-effectiveness ratio (CER) or incremental 
cost-effectiveness ratio (ICER) of PD pharmacotherapy. Results: Six studies were 
selected, all in mandarin. The studies were conducted using different study designs 
including cohort, randomised controlled trials (RCT) and retrospective observation. 
None of the studies utilised any HE modelling. Cost-effectiveness comparisons were 
made between levodopa monotherapy with or without benserazide against other 
adjuvant PD pharmacotherapies. Two studies were conducted based on health sys-
tem perspectives, 2 studies on societal perspectives and the remaining 2 studies 
did not report any. Cost components calculated differed between studies. Only 2 
studies investigated the cost-effectiveness of PD treatment using both direct and 
indirect costs. The effectiveness outcomes were mostly determined using either 
Unified Parkinson’s disease Rating Scale (UPDRS), followed by Parkinson’s disease 
Questionnaire (PDQ) or Visual Analogue Quality of Life (VAS-QOL) scale. Only one 
study reported ICER value whereas the remaining studies only reported CER. All 
studies conducted primary data collection for the purpose of the cost-effectiveness 
PRM4
dRugs in constRaint countRies of suB sahaRan afRica
Nyabade G.O.
Go Fishnet Project, Kisumu, Kenya
Objectives: Being from the very land and a son of the same soil. Africa is the 
world’s second-largest also the most poorest most underdeveloped continent. 
With great struggles and constraints in provision of essential drugs and program 
initiatives,its hard to make proper intervention in urgent essential needs of rem-
edies required on a daily basis especially in the wider scope of village population 
on health priorities. MethOds: In 2007, Africa’s dialysis population constituted 
only 4.5% of the world’s dialysis population, with a prevalence of 74 per million 
population (pmp), compared to a global average of 250 pmp. In almost half the 
African countries, no dialysis patients are reported. The prevalence of peritoneal 
dialysis (PD) was 2.2 pmp, compared to a global prevalence of 27 pmp, with the bulk 
of African PD patients (85%) residing in South Africa. In North African countries, 
which serve 93% of the Results: African dialysis population, the contribution of 
PD to dialysis is only 0% – 3%. Cost is a major factor affecting the provision of 
dialysis treatment and many countries are forced to ration dialysis therapy. Rural 
setting, difficult transportation, low electrification rates, limited access to improved 
sanitation and improved water sources, unsuitable living circumstances, and the 
limited number of nephrologists are obstacles to the provision of PD in many coun-
tries. cOnclusiOns: The potential for successful regular PD programs in tropical 
countries has now been well established. Cost is a major prohibitive factor but the 
role of domestic manufacture in facilitating widespread use of PD is evidenced by 
the South African example. Education and training are direly needed and these are 
areas where international societies can be of great help.
PRM5
is chinese syndRoMe necessaRy in the effectiveness evaluation of 
chinese heRBal foRMulas?
Chen Z.H.1, Yang G.L.1, Zhang Z.2, Zhang H.Y.2, Wang Y.2, Liu GY.1, Qiu Q.3
1Liaoning University of Traditional Chinese Medicine, Shenyang, China, 2Affiliated Hospital 
of Liaoning University of Traditional Chinese Medicine, Shenyang, China, 3Dalian Hospital of 
Traditional Chinese Medicine, Dalian, China
Objectives: Though Chinese herbal medicine had been proofed effective in clinical 
practice, due to the lack of suitable outcomes, the current randomised controlled 
trial studies (RCT) mostly stated that Chinese herbal formulas uneffective, thus the 
effectiveness are rarely confirmed publicly. In this study we applied Chinese syn-
dromes in the effectiveness evaluation of Chinese herbal formulas and to assess their 
suitability and necessity. MethOds: In an finished RCT research, angina patients 
with Phlegm and Blood stasis syndrome were randomized into experimental group 
(Chinese herbal formulas combined with western basic therapy) and placebo group 
respectively. An Chinese questionnaire TCM-SAQ, Seattle Angina Questionnaire (SAQ), 
and SF-12 were applied as patients reported outcomes to evaluate the effectiveness. 
And the results shows that there is no statistical difference in SF-12 and SAQ between 
two groups after 8 weeks’ treatment, while there is significant difference shown in 
the syndrome domain of TCM-SAQ. On the basis of these results, the deviation value 
of all the domains in each questionnaire from the baseline to after 8 weeks’ treat-
ment were calculated. And then the Pearson correlation of the deviation value among 
the domains in TCM-SAQ with domains in SAQ and SF-12 were analysed. Results: 
The correlation between angina domain in TCM-SAQ with each domain in SAQ and 
SF-12 is from 0.045 to 0.237 (p< 0.01), physical limitation domain is 0.450 to 0.779 
(p< 0.01), sleep quality domain is 0.342 to 0.555(p< 0.01), Chinese syndrome domain is 
0.477 to 0.688 (p< 0.01), worry of disease domain is 0.439 to 0.709 (p< 0.01), treatment 
satisfaction domain is 0.298 to 0.689 (p< 0.01). For Chinese syndrome domain the 
correlation with domains in SAQ and SF-12 were all higher than 0.4 and lower than 
0.7. cOnclusiOns: As an patients reported outcome, Chinese syndrome can reflect 
the effectiveness of Chinese herbal formulas. And it is in some degree suitable and 
necessary in the effectiveness evaluation of Chinese herbal formulas.
PRM7
a novel BRoadly aPPlicaBle Risk scoRe foR PRedicting MoRtality of 
Patients with ciRculatoRy systeM diseases within hosPitalization 
duRation
Qu Z.1, Song J.1, Zhan S.2, Ma X.1
1Peking University, Beijing, China, 2Peking University, Beijing, Beijing, China
Objectives: The common comorbidity indexes was developed about two dec-
ades ago and were not appropriate for inpatients risk adjustment nowadays. Our 
objective was to develop a risk stratification model that broadly predicts mortality 
risks in hospitalized patients with circulatory system diseases. MethOds: The 
risk score model was generated by using inpatient summary report of electronic 
medical record dataset from 2006 to 2010 among 50 tertiary hospitals in Beijing, 
and validated by same dataset of 65 tertiary hospitals in the whole country in 
2012. The patient diagnosis as identified by using the International Classification of 
Diseases, 10th Revision. Risk score was developed with individual major diagnostic 
codes. Receiver operating characteristic (ROC) analysis was used to evaluated the 
predictive effect of risk score, and the Charlson Comorbidity Index (CCI) was used 
to compare with the risk score in validation data sets. Results: The diagnosis code 
of total 4,216,375 patients were used to generate the risk scores which comprise 293 
items out of more than 4,000 categories and ranged from 96 to 1. In the validation 
data set, the ROC was 0.845 compared with the CCI ROC of 0.748 among myocardial 
infarction inpatients, and in coronary artery bypass grafting(CABG) inpatients the 
ROC was 0.729 to CCI ROC of 0.626, in percutaneous coronary intervention(PCI) 
inpatients the ROC was 0.847 and 0.648 respectively. The ROC of novel risk score 
was improved 12.7, 16.4 and 30.1 percent among inpatients with circulatory system 
disease. cOnclusiOns: This study generated a broadly applicable tool for risk 
adjustment that predicts circulatory system diseases inpatient mortality with more 
reliability than current risk indexes. This risk index will allow comorbidity-adjusted 
outcomes broadly in surgery, hospitalization and drug efficacy evaluation.
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Association (CHIRA) data is explored. The advantages and limitations of the CHIRA 
data are described. Results: Although there have been abstract disclosures in 
scientific conferences, a search in PubMed (January 8, 2014) found no manuscripts 
published that presented analyses using CHIRA data. It uses ICD-10 codes and col-
lects cross-sectional data annually from inpatient claims records from sample cit-
ies. Advantages include the availability of demographics, institution, diagnoses, 
medications, service use, hospital stay, insurance type and service cost information 
for a large, diverse local population.  Limitations include the lack of longitudinal 
patient records, incomplete data, the lack of outpatient data and standardized bill-
ing codes, and limited access for research purposes. cOnclusiOns: At present 
claims data in China are relatively difficult to access and to use. However the use 
of claims data for health services research is expected to increase in line with 
planned enhancements to data availability and quality, and the increasing needs 
for RWE by decision makers.
PRM14
Managing congenital and PediatRic caRdiac suRgeRy data Base: the 
iMPact on clinical PRactice and Quality of caRe
Furnaz S.
Aga Khan University and Hospital, Karachi, Pakistan
Objectives: To develop a functional and validated database for quality assur-
ance and improving patient outcomes and establishing institutional integ-
rity. MethOds: The Cardiothoracic surgery division at the Aga Khan University 
Hospital maintains a computerized database of all the patients undergoing cardiac 
surgery since July 2006. For this study, data of 1236 patients operated between July 
2006 and Dec 2013 was analyzed. Major measures of outcomes included in-hospital 
and 30 day mortality and morbidity outcomes like reopening, sepsis prolong venti-
lation, arrhythmias low cardiac output syndrome. Results: Out of a total of 1236 
heart surgeries, the most common open heart surgeries were VSD 27%, TOF 24% 
were, and 13% were ASD. In closed heart 51% were Modified BT shunts, 17% were 
PDA. The overall 30-day mortality in open heart was 7.0%, and in closed heart it 
was 7.3%. Post-surgery more common  complication  in open heart surgery was 
prolong ventilation which was 39%,arrhythmias 14%,reopenings 11% and sepsis 
5%total morbidity was 29% while in closed heart most common complication 
was prolong ventilation which was 31%, total morbidity was 21%. Readmissions 
after 30 day of Discharge were 8.4% mainly for respiratory infection. Followed 
with 14% lost to follow-ups 85% patients were alive, 0.6% were died at 30 day 
patients follow up. chAnges depend On dAtAbAse: VSD: on table extubation 
or extubation with 4 hours – minimal morbidity and early discharges. ASD: on 
table extubation. cOnclusiOns: Updated and stringently maintained database 
helped to identify deficiencies, strength and trends of the Pediatric and Congenital 
Cardiac surgery program at our hospital and also to design strategies for continu-
ing improvement in patient care. Also provides scientific evidence for comparing 
results with other institutions of the region and world.
PRM15
develoPMent of a longitudinal national footBall league injuRy 
and injuRy iMPacts (l-nfl-iii) dataBase
Markowitz J.S.1, Papadopoulos G.2, Markowitz A.3
1Health Data Analytics, Princeton Jct., NJ, USA, 2Emerald Corporate Group P/L, McMahons Point, 
Australia, 3Consultant, San Salvador, El Salvador
Objectives: Injuries in sports, including professional American football, are a 
major public health problem affecting millions of young and adult athletes around 
the world each year. While most injuries are minor, some end seasons, careers, and 
may even result in long-term disability. No outcomes databases exist that focus 
on injuries in the National Football League (NFL). We sought to develop a database 
that’s longitudinal and includes key injury impact outcomes. MethOds: Four years 
of data including information on any player that played 1+ regular season games 
between 2010 and 2013 were adapted from NFL.com, ESPN.com, TSN.com and sev-
eral other reputable online sources. Five different and unique data types, all capable 
of being merged with one another and used in longitudinal analyses, were stored 
as SAS datasets: Player Background (e.g., age, weight, position), Games Played, NFL 
Injury Report, Injured Reserve List, and Schedule and Conditions (e.g., field sur-
face, weather conditions, referee).  Data from the NFL Injury Report and Injured 
Reserve List contain every significant injury to NFL players during the 4-year period 
including concussions, knees, ankles, hamstrings, etc. Injury Impacts include games 
missed due to injuries as well as season- and career-ending injuries. Results: 
Data on 3,193 unique NFL players are included in the database. About 7,700 player-
seasons are captured that cover nearly 91,000 player-games. About 18,500 Injury 
Reports are recorded on these players resulting in more than 6,000 missed games. 
In addition, almost all 959 Injured Reserve List injuries are season-ending and sig-
nificantly raise the risk of ending a player’s career. cOnclusiOns: The L-NFL-III 
database can be a useful tool for epidemiological and outcomes research related to 
injuries in the NFL. In 4-year longitudinal analyses, this database was successful 
in identifying a large number of missed games due to injuries, as well other critical 
outcomes including season- and career-ending injuries.
PRM16
health caRe dataBases aPPlied to antidePRessants use in  
asia-Pacific
Milea D.1, Reginald P.2, Saragoussi D.3, Kalita P.4, Verpillat P.5, Azmi S.2
1Lundbeck Singapore Pte Ltd., Singapore, 2Azmi Burhani Consulting, Petaling Jaya, Malaysia, 
3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck Singapore Pte Ltd, Singapore, 5Lundbeck 
SAS, Issy-les-Moulineaux Cedex, France
Objectives: Health care databases represent an optimal tool for conducting large 
retrospective epidemiological studies and are largely used in Europe and the US. 
This study is the second phase of an earlier study which qualititatively describes 
databases in Asia Pacific. In this phase, we focused on several countries that have 
large health care databases used for administrative functions namely South 
analysis. The time horizon for each studies ranged from 2-3 months in the RCTs, 
and 1-24 months in the observational studies. No discounting was reported in any 
of the articles. Only one article reported sensitivity analysis. cOnclusiOns: All HE 
studies published were piggy-backed to clinical studies and none utilised HE model-
ling.  None of the HE studies completely fulfilled the standard HE reporting criteria.
ReseaRch on Methods – databases & Management Methods
PRM11
assessMent of need, develoPMent and iMPleMentation of 
suPPoRtive ManageMent dataBase foR the tReatMent of Poisoning 
cases in a teRtiaRy caRe hosPital
Nikhil B.1, Thunga G.1, Pariti B.2, Varma M.3
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Manipal 
University, Manipal, India, 3KMC, udupi, India
Objectives: The main purpose of the present study was to assess the physicians 
need for the development of a supportive management database for the treatment 
of poisoning cases and to implement such a database in the hospital setup based on 
the need of the physicians. MethOds: A prospective, observational study was con-
ducted in the emergency department of Kasturba Hospital, Manipal. The study was 
approved by the Institutional Ethics Committee of Kasturba Hospital, Manipal. A 12 
item questionnaire was developed, validated and given to 42 physicians who treated 
acute poisoning cases to assess their need for the development and implementation 
of a supportive management database. Material for the database was prepared after 
conducting an electronic literature search of various existing databases. Results: 
The 12 item questionnaire was given to seven experts for content validation. Out 
of twelve items, one item was excluded from the final questionnaire as it did not 
meet the required value. All 42 (100%) of the physicians believed that a supportive 
management database for poisoning cases in the hospital setup would be really 
helpful. Over 300 articles were referred in the preparation of the material for the 
database. cOnclusiOns: Clinical pharmacists together with physicians who treat 
poisoning cases must work hand in hand in developing institutional guidelines for 
the management of poisoning. Development of such guidelines could reduce the 
complications and mortality which are associated with poisoning cases.
PRM12
evidence foR validity of a national Physician and Patient-RePoRted 
suRvey in china and united kingdoM: the disease sPecific PRogRaMMe
Babineaux S.M.1, Curtis B.H.1, Holbrook T.2, Liu L.3, Colclough H.4, Piercy J.4
1Eli Lilly & Company, Indianapolis, IN, USA, 2Adelphi Real World, Bollington, UK, 3Eli Lilly Suzhou 
Pharmaceutical Co. Ltd., Shanghai, China, 4Adelphi Real World, Cheshire, UK
Objectives: Traditional large scale epidemiological surveys used to inform public 
health decision-making have limitations, notably the cost and time to administer 
them and the timeliness of the data, sometimes subject to 5 or more years between 
updates. This analysis aimed to validate a newer survey methodology by comparing 
output with that from two large scale health surveys. MethOds: Data were drawn 
from the Adelphi Diabetes Disease Specific Programme (DSP), a cross-sectional sur-
vey of physicians and their patients conducted in China (2012) and United Kingdom 
(UK) (2013). Detailed records for 1662 patients were provided by 200 physicians 
in China. In the UK, 125 physicians provided records for 1237 patients.  Clinical 
and demographic characteristics of the samples were compared with independ-
ent representative national data sources:  a 2007/08 Chinese epidemiology study 
(46,239 patients) and the Health Survey for England 2011 (HSFE), administered to 
10,000 individuals. Variables common to both datasets were compared and tested 
for significant differences. Results: Systolic blood pressure (SBP) and low-density 
lipoprotein (LDL) values from the China DSP were statistically non-different from 
the national survey. There were differences between fasting plasma glucose (137.8 
vs. 158.6); age (56.6 vs. 55.8); male body mass index (BMI) (24.1 vs. 25.2) and high-
density lipoprotein. Comparing the UK DSP with the HSFE, all variables (age, gender, 
smoking status, age at diagnosis (61.5 vs. 63.9), insulin-treated, BMI (31.6 vs. 32.3), 
total cholesterol, HBA1C% (7.768 vs. 7.981), and SBP were non-different. Weeks since 
diagnosis differed - 358 DSP vs. 504 HSFE. cOnclusiOns: Results demonstrate that 
the DSP methodology enables up-to-date representative sampling of treated adult 
patients in Western and Asian populations for national disease burden quantifica-
tion, and treatment pattern and outcomes assessment. A limitation is that sampled 
patients are more recently diagnosed, but there are otherwise only minor differ-
ences in clinical and demographic characteristics.
PRM13
Real woRld evidence in Mainland china: exPeRience with the use of 
health caRe claiMs data
Yang Y.1, Zhang J.2, Du F.3, Montgomery W.4, Li H.5, Flynn J.A.6
1Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China, 2China Health Insurance Research 
Association, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, 4Eli 
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Lilly Japan K.K., Kobe, Hyogo, Japan
Objectives: The China public health insurance system now covers 95% of the 
population due to efforts to establish universal coverage under three primary gov-
ernment programs (Urban Employee Basic Medical Insurance, Urban Resident Basic 
Medical Insurance, and New Rural Cooperative Medical Scheme).  Data from these 
insurance programs are combined to create the China Health Insurance Association 
(CHIRA) database; the only national claims database in China.  Use of these data 
allow research to examine patients, settings, patterns and outcomes that may dif-
fer from that of RCTs; advancing China’s population-based research and enhanc-
ing the opportunity to apply real world evidence (RWE) in local decision making.  
The use of claims data is relatively uncommon in China. This work explores the 
current and potential use of local claims data as a source of information for RWE 
in China. MethOds: The experience of the use of the China Health Insurance 
